by Lucy Prior | Jul 31, 2023 | Press Releases, Welcome
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech...
by Lucy Prior | May 2, 2023 | Welcome
Isogenica turns 25: Our journey We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Like many long-standing businesses, we’ve been through many changes to get to where...
by Lucy Prior | Mar 28, 2023 | Press Releases, Welcome
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship Announcing a further collaboration with the Frederick National Laboratory for Cancer Research The relationship between Isogenica and...
by Lucy Prior | Jan 18, 2023 | Press Releases, Welcome
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display...
by Philippa Shelton | Nov 7, 2022 | Welcome
PEGS 2022: Isogenica showcases plans for implementing machine learning tools Isogenica is attending PEGS Europe: Protein and Antibody Engineering Summit, 14-16th November 2022 Isogenica is delighted to announce we’re attending PEGS Europe 2022. ...
by Philippa Shelton | Nov 4, 2022 | Welcome
Isogenica VHH antibodies used in potential therapy for heart failure Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for...